PARP (poly ADP-ribose polymerase) inhibitors are currently used to treat inoperable or recurrent breast cancer that is germline BRCA pathogenic/likely pathogenic mutation-positive and HER2-negative with a history of prior cancer chemotherapy [45]. Here, ERBB2 is linked to breast carcinoma.